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In recent years numerous collaborative studieshave been conducted all over the world on thetreatment of pediatric malignant neoplasms.
The aim of these studies was to collect data on
clinical and biological features in order to identify
prognostic factors and different subgroups of dis-
ease with different clinical relevance to improve the
treatment. Such collaborative studies have led
pediatric oncology to achieve important goals in
our understanding of the pathogenesis, diagnosis
and treatment of neoplastic diseases. An essential
premise for multicentric studies is that all cases, or
at least the majority of them, can be adequately
analyzed using current evaluation techniques.
The cytogenetic analysis of leukemic blasts in
childhood acute lymphoblastic leukemia (ALL) has
identified chromosome abnormalities in about 50-
80% of cases.1 The presence of well-defined struc-
Background and Objective. Cytogenetic analysis
of acute leukemia yields important information
which has been demonstrated to be correlated to
patient survival. A reference laboratory was creat-
ed in order to perform karyotype analysis on all
cases of acute leukemia enrolled in the AIEOP
(Associazione Italiana Emato-Oncologia Pediatrica)
protocols.
Methods. From January 1990 to December 1995,
1115 samples of children with ALL or AML were
sent in for cytogenetic analysis. The results of cell
cultures were screened in the Reference Laboratory
and then the fixed metaphases were sent to one of
the six cytogenetic laboratories for analysis. 
Results. The leukemic karyotypes of 556 patients
were successfully analyzed. An abnormal clone was
detected in 49% of cases of ALL and in 66% of
AML. In ALL the most frequent abnormality was
9p rearrangement. Other recurrent abnormalities
were t(9;22), t(4;11) and t(1;19). In AML t(8;21),
t(15;17) and 11q23 rearrangement were the most
frequent structural abnormalities. These findings
are similar to the results obtained in other multi-
center studies using a similar approach.
Interpretation and Conclusions. Our data con-
firm the feasibility of performing cytogenetic analy-
sis in a centralized laboratory on mailed samples
of bone marrow and/or peripheral blood; this is
very important considering that cytogenetic analy-
sis of neoplastic tissue requires a special laborato-
ry and expert staff.
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ABSTRACT
tural abnormalities in children with ALL correlates
with a different prognosis and with different treat-
ment. In the latest BFM family protocol, the pres-
ence of the t(9;22) and t(4,11) translocation is
considered to be an independent factor indicating
a poor prognosis and prompting a high-risk thera-
peutic program.1-5
Other abnormalities, such as t(8;21), t(15;17),
are associated with a particular subtype of acute
myeloblastic leukemia (AML);6 in all such cases
cytogenetic results are crucial in the choice of treat-
ment. Cytogenetic analysis is consequently stan-
dard practice nowadays in the diagnostic approach
to leukemia, but very accurate culturing methods
and considerable technical expertise are needed for
proper karyotype analysis of acute leukemia.
Since 1990, the Onco-Hematology Laboratory of the
Pediatric Department at Padua University has per-
formed cytogenetic analysis on acute leukemia
samples, together with diagnostic and biological
studies, on request for any institution following the
AIEOP protocols.
This paper presents an overview of the results of
this collaborative cytogenetic study which involved
several AIEOP centers and a few cytogenetic labora-
tories between 1990 and 1995. The aim of this
paper was to establish the feasibility of centralizing
cytogenetic studies and to compare the outcome of
this approach with other collaborative studies.
Materials and Methods
Patients
In 1988 a tissue bank for the storage of bone
marrow and peripheral blood samples of pediatric
patients enrolled in the therapeutic trials of the
AIEOP was created in Padua at the Onco-Hematol-
ogy Laboratory, a reference laboratory where mor-
phological evaluation and immunophenotyping
were also performed.7 A year later, all the AIEOP
centers unable to perform cytogenetic investiga-
tions in their own laboratories were given the
opportunity to send a heparinized bone marrow
sample to the central laboratory, together with a
sample for the bone marrow bank, thus avoiding
any extra cost of mailing the sample for cytogenetic
analysis alone. 
Between January 1990 and December 1995, 1309
samples of bone marrow and/or peripheral blood
from children with suspected acute leukemia were
sent to Padua for cytogenetic evaluation; 1115 of
these were ALL or AML at diagnosis or relapse. The
other 193 samples belonged to patients with non-
neoplastic diseases, and these cases were excluded
from the study. The 1115 leukemia patients were
enrolled in the AIEOP protocols after informed con-
sent was obtained. There were 667 males and 448
females; their ages ranged from 1 day to 16 years.
All the cases were classified according to the
French-American-British (FAB) classification8,9 and
were studied according to the minimal require-
ments of the BFM-family group criteria for the eval-
uation of childhood acute leukemia.10
Cytogenetic analysis
Heparinized bone marrow and/or peripheral
blood samples were collected in syringes or test
tubes and mailed to the laboratory at room tem-
perature with next-day delivery, 48 hours were
required for samples sent from Sicily and Sardinia.
A white blood cell count of the sample was
obtained, and cell vitality was checked; cultures
were prepared using 13106 cells/mL of medium
(RPMI 1640, 20% FCS, L-glutamine and 50 ng/mL
penicillin/streptomycin). When an adequate num-
ber of cells was available, three different cultures
(for direct harvest, overnight exposure to colchemid
and 24-hour culture) were prepared. In the cases of
AML, an additional culture was incubated for 3
days with a supernatant of a cell line with growth
factors.11 Any samples without vital cells, or those
with fewer than 53106, or with EDTA used as an
anticoagulant, were classified as unsuitable and
excluded from the analysis. Routine methods were
used for culture harvesting and chromosome
preparation. The results of cell culture were
screened in the reference laboratory. 
The cell suspensions containing analyzable
metaphases were sent to one of the cytogenetic lab-
oratories in Genoa (MS), Pavia (FP, EM), Perugia
(ED), Pisa (PS, CG), Rome (AA), or Vicenza (MS,
AM), where cytogenetic analysis was performed
using routine methods. From 1 to 3 slides were
screened in each case and 10-20 metaphases were
analyzed. Chromosomes were identified and
assigned according to the International System for
Human Cytogenetic Nomenclature.12 Cell culture failure
was defined as cases where fewer than 10 well-ana-
lyzable metaphases were found. The cytogenetic
results were resubmitted to the reference laborato-
ry, where all data were recorded and sent back to
the center to which the patient belonged.
Results
The 1115 samples of acute leukemia analyzed
included: 951 cases at diagnosis (802 ALL and 149
AML) and 164 at relapse (134 ALL and 30 AML).
All the patients joined the AIEOP protocols for
childhood ALL or AML. The number of AIEOP cen-
ters requesting cytogenetic analysis has progressively
increased over the years, from 12 in 1990 to 27 in
1995.
Of the 1115 samples received, 391 (35%) were
unsuitable for cytogenetic analysis due to the low
number of cells for cultures (< 5 million), the lack
of vital cells in the sample, clotting or the use of an
unsuitable anticoagulant; these samples were con-
sequently excluded from the study (unsuitable sam-
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ples). A karyotype was not definite in 15% of the
cases because a very low mitotic index or poor-
quality metaphases were obtained from the cell cul-
ture (168 cell culture failures).
The proportion of suitable samples did not vary
consistently over the years; this proportion derives
from the inadequacy of the samples delivered in
some instances.
In ALL, unsuitable samples were the main reason
for the failure of the cytogenetic analysis (40%)
(Table 1a), whereas in the AML they amounted to
15% (Table 1b).
We successfully analyzed the leukemic karyotype
of 556 patients, identifying 296 cases with an
abnormal clone. In ALL these results were almost
all obtained from direct harvesting and overnight
cultures, the latter being the most successful. In
AML, the results were obtained from overnight cul-
tures and from cultures with added growth factors,
as described in the methods.
In the ALL group, the percentage of cases with an
abnormal clone varied over the years between 35%
and 60% (Table 2). In the AML group, an abnormal
clone was observed in 53% and 77% of the cases
(Table 3). In the last three years, an abnormal clone
was always detected in more than 50% of ALL.
Table 4 shows the distribution based on the immu-
nophenotype of the recurrent structural abnormali-
ties found in ALL at diagnosis. The most frequent
abnormality in our series was the rearrangement of
the short arm of chromosome 9, which was found
in 14 cases with either the B or the T phenotype.
Twelve cases presented t(9;22), 8 of these were C-
ALL, 1 prepreB, 2 preB and 1 had a hybrid pheno-
type; t(1;19) was detected in 8 cases, all of which
were preB ALL; t(4;11) was detected in 6 cases, 4 of
which were C-ALL, 1 was a prepre B ALL and 1 pre-
sented a hybrid phenotype.
Table 5 shows the ploidy distribution by immu-
nophenotype in ALL at diagnosis in our series. 
The most frequent group in the cases with abnor-
mal karyotypes is the pseudodiploid (70 cases,
21%); a hyperdiploid karyotype with more than 50
chromosomes was found in 37 cases (11%), and
with 47 to 50 chromosomes in 30 cases (9%). A
hypodiploid karyotype was observed in 19 cases
(5%).
Tables 6 and 7 show the distributions of recur-
rent structural abnormalities and ploidy according
to FAB subgroups in AML at diagnosis. The most
frequent structural rearrangements were the recip-
rocal translocations t(8;21) in the M1/M2 (11
cases) and t(15;17) in the M3 (12 cases) FAB sub-
Table 1. Results of centralized cytogenetic analysis.
a. ALL results
1990 1991 1992 1993 1994 1995 Total 
cases
Unsuitable 21 46 45 72 90 91 365
samples (33%) (49%) (32%) (36%) (42%) (40%) (40%)
Cell culture 13 8 29 26 40 33 149
failure (21%) (9%) (21%) (13%) (19%) (15%) (16%)
Suitable 29 39 65 104 83 103 423
cases (47%) (42%) (47%) (51%) (39%) (45%) (44%)
Total 63 93 139 202 213 227 937
cases (100%) (100%) (100%) (100%) (100%) (100%) (100%)
b. AML results
1990 1991 1992 1993 1994 1995 Total 
cases
Unsuitable 3 3 2 7 7 4 26
samples (14%) (16%) (9%) (18%) (20%) (9%) (15%)
Cell culture 2 3 1 5 6 2 19
failure (9%) (16%) (5%) (13%) (17%) (5%) (11%)
Suitable 17 13 18 26 22 37 133
cases (77%) (68%) (86%) (69%) (63%) (86%) (74%)
Total 22 19 21 38 35 43 178
cases (100%) (100%) (100%) (100%) (100%) (100%) (100%)
Cases were classified as "unsuitable" or as "cell culture failures" according
to the criteria  mentioned in the "Materials and Methods" section.
Table 2. Proportion of ALL cases with normal and abnormal
karyotypes per year.
1990 1991 1992 1993 1994 1995 Total 
cases
Normal 18 23 42 42 42 48 215
(62%) (59%) (65%) (40%) (50%) (47%) (51%)
Abnormal 11 16 23 62 41 55 208
(38%) (41%) (35%) (60%) (50%) (53%) (49%)
Total 29 39 65 104 83 103 423
(100%) (100%) (100%) (100%) (100%) (100%) (100%)
Table 3. Proportion of AML cases with normal and abnormal
karyotypes per year.
1990 1991 1992 1993 1994 1995 Total 
cases
Normal 8 3 6 10 6 12 45
(47%) (23%) (33%) (38%) (27%) (32%) (34%)
Abnormal 9 10 12 16 16 25 88
(53%) (77%) (67%) (62%) (73%) (68%) (66%)
Total 17 13 18 26 22 37 133
(100%) (100%) (100%) (100%) (100%) (100%) (100%)
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groups. A rearrangement with a breakpoint in
11q23 was detected in 7 cases; 1 case showed a
rearrangement of chromosome 11 at q21. Isolated
trisomy 8 and 21 were documented in 10 and 6
cases, respectively. Monosomy 7 was found in 4
cases. On the whole, our results demonstrate that
the most frequent clonal karyotype alteration in
AML was pseudodiploidy, detected in 45% of cases,
while metaphases with a number of chromosomes
between 47 and 50 were found in 15% of cases; few
cases presented a hypodiploid (3%) or hyperdiploid
(2%) karyotype with more than 50 chromosomes. 
Discussion
Since several multicenter studies on childhood
acute leukemia have been conducted all over the
world, we now have a considerable number of
equally-studied and homogeneously-treated cases.
Most of our understanding of the biology and
treatment of leukemias comes from such coopera-
tive studies in children.
Since 1990, the reference laboratory for all the
AIEOP centers has performed cytogenetic analysis
and all other diagnostic and biological procedures
on request.
Collecting many samples at a single laboratory
reduces the costs and enables hospitals with no
cytogenetic laboratory of their own to have this
analysis done inexpensively. The addition of the
cytogenetic analysis facility to a pre-existing biologi-
cal bank has meant a further reduction in costs and
an easier procedure for the doctor responsible for
the patients and who requests the analysis. Over
Table 4. Recurrent cytogenetic abnormalities by immunopheno-
type in ALL at diagnosis 1990-95.
No. of pre- preB B C-ALL T Hybrid nd
cases preB
t(1;19)(q23;p13) 8 – 8 – – – – –
t(9;22)(q34;q11) 12 1 2* – 8 – 1 –
t(4;11)(q21;q23) 6 1 – – 4§ – 1 –
der(11)(q23) 2 – – – 2 – – –
t(8;14)(q24;q32) 1 – – 1 – – – –
der(14)(q11-q13)∑ 5 – – – – 5 – –
t(7;7)(p15;q36) 1 – – – – 1 – –
der(6)(q21-q23) 6 – 2 – 3 – – 1
del(9)(p21)/der(9p) 14 2 5 – 2 4 – 1
der(12)(p) 4 – – – 2 1 1 –
-20/20q- 9 – 3 – 6 – – –
+21^ 4 – – – 4 – – –
•t(1;14),t(11;14),t(8;14); * variant translocations t(9;20;22)(q34;?;q11),
t(8;22)(q24;q11); § variant translocation t(2;4;11)(q14;q21;q23); 
^unassociated with other numerical abnormalities in non-Down patients;
nd: immunophenotype not defined.
Table 6. Recurrent cytogenetic abnormalities by FAB groups in
AML at diagnosis 1990-95 .
No. of MO M1 M2 M3 M4 M5 M6 M7
cases
t(8;21)(q22;q22) 11 – 3 8 – – – – –
t(15;17)(q22;q12) 12 – – – 12 – – – –
der(11)(q23) 2 – – – – 2 – – –
t(9;11)(p22;q23) 2 – – – – 1 1 – –
t(11;19)(q23;p13) 2 – – – – – 2 – –
t(8;16)(p11;p13) 2 – – – – – 2 – –
t(10;11)(p13;q21) 1 – – – – – 1 – –
inv(16)(p13q22) 1 – – – – 1 – – –
der(6)(q) 2 1 1 – – – – –
t(6;9)(p23;q34) 2 – 1 – – 1 – – –
t(9;22)(q34;q11) 1 – 1 – – – – – –
t(4;11)(q21;q23) 1 – 1 – – – – – –
del(9)(q22) 2 – – 2 – – – – –
+8* 10 1 1 1 1 2 3 1 –
+21* 6 – 3 1 – 1 1
–7 4 2 1 – – 1 – – –
Others 14 3 4 1 – 4 – 1 1
*unassociated with other numerical abnormalities in non-Down patients.
Table 7. Distribution of FAB groups by ploidy in AML at diagno-
sis 1990-95.
No. of FAB groups
cases (%) MO M1 M2 M3 M4 M5 M6 M7 nd
Hyperdiploid (>50) 3 (2%) – 1 – – – 2 – – –
Hyperdiploid (47-50) 17 (15%) – 5 2 1 2 3 1 1 2
Diploid (normal) 38 (35%) 1 7 2 4 4 10 – 3 7
Pseudodiploid 49 (45%) 3 8 7 11 8 9 1 – 2
Hypodiploid 4 (3%) – 1 1 – 1 – – – 1
Total 111 4 22 12 16 15 24 2 4 12
nd: FAB not defined.
Table 5. Distribution of immunophenotype by ploidy in ALL at
diagnosis 1990-95.
No. of pre- preB B C-ALL T Hybrid nd
cases preB
Hyperdiploid (>50) 37 (11%) – 7 24 – – – 6
Hyperdiploid (47-50) 30 (9%) 1 9 14 – 5 – 1
Diploid (normal) 188 (54%) 1 54 79 1 24 6 23
Pseudodiploid 70 (21%) 2 16 30 2 12 3 5
Hypodiploid 19 (5%) – 3 12 – 2 – 2
Total 344 4 89 159 3 43 9 37
nd: immunophenotype not defined.
the years, the number of samples sent to our labo-
ratory has increased progressively, demonstrating
the value of this organization in Italy at this time.
The slides with chromosome preparations were
split between different cytogenetic laboratories in
order to reduce the response time.
A considerable number of samples were lost due
to incorrect sampling and preserving methods. The
most frequent causes were: faulty cell harvesting
methods at bone marrow aspiration; the use of
EDTA as an anticoagulant; coagulation of the sam-
ple; and contamination of the blood. The percent-
age of unsuitable samples is higher in the ALL
group, probably due to the difficulty in retrieving a
large number of blasts by bone marrow aspiration
at diagnosis in a consistent number of these
leukemia cases, and to problems specific to ALL
samples. The percentage of unsuitable samples has
not improved with time, possibly because the num-
ber of centers sending the samples is increasing, so
new centers taking part in the study every year may
be responsible for our failure to contain this waste
of material. On the other hand, given the large
number of suitable samples submitted for cytoge-
netic analysis, our experience confirms the feasibili-
ty of performing cytogenetic analysis on mailed
samples of leukemic cases, as reported in the BFM
experience.5 The percentage of successful cultures
with correct sampling and preserving methods
ranged from 68% to 83% for the ALL cases (a total
of 672 cases) and from 79% to 95% for the AML
cases (a total of 152 cases). 
An abnormal karyotype was detected in 208 cases
of ALL (49%) and in 88 cases of AML (66%). These
results are similar to the findings of a BFM multi-
center study conducted on 1843 children with acute
leukemia.2 Lampert reports a cytogenetic success in
55-60% of ALL and in 70% of AML, with a propor-
tion of abnormal karyotypes of 60% in ALL and 68%
in AML. The percentage of samples with no
metaphases, or with a normal karyotype, is report-
edly lower among most of the single-center groups
with extensive experience than it is in our series,13
though it is not very dissimilar from other reports.14
In the French cooperative study on karyotypes in
childhood leukemia, clonal abnormality was found
in a higher percentage of ALL (71%); but this collab-
oration was organized differently from ours, i.e. in
the French cooperative study, karyotype analysis
was performed by each hospital and then the kary-
otypes were reviewed by all those taking part in the
group.15 On the other hand, the existence of a cen-
tral laboratory gives everyone the opportunity to
have cytogenetic investigations performed, and thus
retrieves many samples that would otherwise be lost
for the purposes of cytogenetic analysis. It is also
worth noting the fact that our efficiency in detecting
abnormal clones has improved in the latter years of
our work (Tables 2 and 3), both in ALL and in AML,
and a more careful handling of the samples should
enable us to improve on the standard of results. 
The distribution of the clonal abnormalities
detected in ALL at diagnosis (Table 5) is similar to
the one of the German cooperative study.2
At this stage, we cannot discuss the leukemic
karyotype in detail, since the aim of this study was
to verify the feasibility of a cytogenetic cooperative
study for analyzing childhood acute leukemia.
Our results indicate that overnight exposure to
colchemid gives the best chances of success in ALL,
in terms of metaphases; whereas in AML, evaluable
metaphases are obtained from the three short-term
cultures, as the addition of growth factors, is useful.
In conclusion, we believe that our data confirm the
feasibility of using a centralized laboratory to carry
out cytogenetic analysis on mailed samples of bone
marrow and/or peripheral blood of acute leukemia.
This approach is not only an easy, inexpensive solu-
tion for gaining complete information in multicen-
ter studies, but it also creates easily-accessible stor-
age of material and information available for further
studies, being the base of future investigations.
Some cytogenetic abnormalities with recognized
clinical significance can now be screened using a
molecular biology method,16,17 but others with vari-
ant or as of yet unknown structures cannot be iden-
tified by molecular biological methods. It is also
very important to continue looking for other abnor-
malities that might be relevant in the diagnosis,
treatment and follow-up of leukemia,18,19 confirming
the relevance of cytogenetic analysis in acute
leukemia.
Our data confirm the feasibility of cytogenetic
analysis performed in a centralized laboratory on
mailed samples of bone marrow and/or peripheral
blood of acute leukemias; this could be a very help-
ful approach in multicenter studies, overcoming the
bias of the limited number of laboratories available
for cytogenetic analysis. In fact, the cytogenetic
analysis of the neoplastic tissue requires a special
laboratory with an expert staff.
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